Information;Judgment — ECLI:EU:T:2026:13
Date: 2026-01-14
Language of the case: English
Court formation: Eighth Chamber
Procedure: Action for annulment
Origin: Spain

Judgment of the General Court (Eighth Chamber) of 14 January 2026 – Ionfarma v EUIPO – Manola and Simeone (DESMOMED) (Case T‑230/25) ( EU trade mark – Opposition proceedings – Application for EU word mark DESMOMED – Prior national word mark DERMOMED – Relative ground for refusal – No likelihood of confusion – No similarity between the goods at issue – Article 8(1)(b) of Regulation (EU) 2017/1001 ) 1. EU trade mark – Definition and acquisition of the EU trade mark – Relative grounds for refusal – Opposition by the proprietor of an identical or similar earlier mark registered in respect of identical or similar goods or services – Likelihood of confusion with the earlier mark – Criteria for assessment (European Parliament and Council Regulation 2017/1001, Art. 8(1)(b)) (see paragraphs 16, 17) 2. EU trade mark – Definition and acquisition of the EU trade mark – Relative grounds for refusal – Opposition by the proprietor of an identical or similar earlier mark registered in respect of identical or similar goods or services – Similarity between the goods or services concerned – Criteria for assessment – Complementary nature of the goods or services (European Parliament and Council Regulation 2017/1001, Art. 8(1)(b)) (see paragraphs 24, 25) 3. EU trade mark – Decisions of EUIPO – Legality – Examination by the EU judicature – Criteria (European Parliament and Council Regulation 2017/1001) (see paragraph 28) 4. EU trade mark – Definition and acquisition of the EU trade mark – Relative grounds for refusal – Opposition by the proprietor of an identical or similar earlier mark registered in respect of identical or similar goods or services – Likelihood of confusion with the earlier mark – Word marks DESMOMED and DERMOMED (European Parliament and Council Regulation 2017/1001, Art. 8(1)(b)) (see paragraphs 33, 47-49) Operative part The Court: 1. Dismisses the action; 2. Orders Ionfarma, SL, and the European Union Intellectual Property Office (EUIPO) each to bear their own costs.